Hear how HTG Molecular is committed to collaborating with our investigators around the globe to address key diagnostic and therapeutic questions that can eventually be translated to empower precision medicine at the local level.
As an example, at the ASCO 2019 Clinical Science Symposium, Dr. William from M.D. Anderson and Hospital BP in Sao Paulo Brazil presented an interesting body of work around the molecular landscape of oral neoplasias and the risk of progression to malignancy.
Our next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets from samples a fraction of the size required by competitive technologies, enabling customers to do more molecular profiling with less sample.
Learn More
Use our HTG EdgeSeq Match Gene:Panel Connection tool to connect your gene of interest to our specific assay. The HTG EdgeSeq panel gene names conform to the names curated by the HUGO Gene Nomenclature Committee part of the NCBI. Aliases may or may not be found in this data bank. The HUGO approved symbol can be found here.
We've added a new feature! Now you can quickly find all available HTG matching gene options using a partial match search. Please note: when inputting a search term, a hyphen may be required to return a match, e.g. miR-129.
HTG EdgeSeq Pan B-Cell Lymphoma panel. The newest addition to our RUO portfolio. It is designed to provide molecular characterization of aggressive lymphomas by allowing researchers to measure the expression of genes associated with the lymphoma transcriptome.
Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director TUCSON, Ariz. , Jan. 19, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that Timothy
Preliminary full year 2020 unaudited revenue of $8.5 million Cash, cash equivalents and short-term marketable securities of $28.7 million as of December 31, 2020 TUCSON, Ariz. , Jan. 05, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose
TUCSON, Ariz. , Dec. 30, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease
TUCSON, Ariz. , Dec. 18, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its
TUCSON, Ariz. , Dec. 08, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq
TUCSON, Ariz. , Nov. 23, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result of its one-for-fifteen reverse stock split which became effective at 5:00 p.m.
At HTG Molecular Diagnostics, Inc., we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.
Sr. Manager/Director Assay Development
Find product information, specifications and gene lists here.
Read white papers or journal publications and view other scientific content.
Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels.
Page last updated February 25, 2021
HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.